NANicholas L. Angeloni

Nicholas L. Angeloni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas L. Angeloni has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher W. Bond

    Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States of America

    7 shared publications
  • Carol A. Podlasek

    Department of Urology, Northwestern University Medical School, Chicago, IL, USA

    4 shared publications
  • Colby Shad Thaxton

    Department of Urology, Northwestern University, 303 E Superior Street, Chicago, Illinois 60611, United States

    4 shared publications
  • Daniel A. Harrington

    Department of Diagnostic and Biomedical Sciences School of Dentistry The University of Texas Health Science Center at Houston Houston Texas USA

    4 shared publications
  • Kaylin M. McMahon

    Department of Urology, Feinberg School of Medicine, Northwestern University, Tarry, Chicago, IL, USA

    4 shared publications
  • Carol A. Podlasek

    Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States of America

    3 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche

    by Michael P. Plebanek, Nicholas L. Angeloni, Elena Vinokour, Jia Li, Anna Henkin, Dalia Martinez-Marin, Stephanie Filleur, Reshma Bhowmick, Jack Henkin, Stephen D. Miller, et al.

    Metastatic cancers produce exosomes that condition pre-metastatic niches in remote microenvironments to favor metastasis. In contrast, here we show that exosomes from poorly metastatic melanoma cells can potently inhibit metastasis to the lung. These “non-metastatic” exosomes stimulate an innate immune response through the expansion of Ly6Clow patrolling monocytes (PMo) in the bone marrow, which then cause cancer cell clearance at the pre-metastatic niche, via the recruitment of NK cells and TRAIL-dependent killing of melanoma cells by macrophages. These events require the induction of the Nr4a1 transcription factor and are dependent on pigment epithelium-derived factor (PEDF) on the outer surface of exosomes. Importantly, exosomes isolated from patients with non-metastatic primary melanomas have a similar ability to suppress lung metastasis. This study thus demonstrates that pre-metastatic tumors produce exosomes, which elicit a broad range of PMo-reliant innate immune responses via trigger(s) of immune surveillance, causing cancer cell clearance at the pre-metastatic niche.


  • Open Access

    Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia

    by Kaylin M. McMahon, Cristina Scielzo, Nicholas L. Angeloni, Elad Deiss-Yehiely, Lydia Scarfo, Pamela Ranghetti, Shuo Ma, Jason Kaplan, Federica Barbaglio, Leo I. Gordon, et al.

    Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia


  • Open Access

    Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1

    by Nicholas L. Angeloni, Kaylin M. McMahon, Suchitra Swaminathan, Michael P. Plebanek, Iman Osman, Olga V. Volpert, C. Shad Thaxton

    Exosomes are produced by cells to mediate intercellular communication and have been shown to perpetuate diseases, including cancer. New tools are needed to understand exosome biology, detect exosomes from specific cell types in complex biological media and to modify exosomes. Our data demonstrate a cellular pathway whereby membrane-bound scavenger receptor type B-1 (SR-B1) in parent cells becomes incorporated into exosomes. We tailored synthetic HDL-like nanoparticles (HDL NP), high-affinity ligands for SR-B1, to carry a fluorescently labeled phospholipid. Data show SR-B1-dependent transfer of the fluorescent phospholipid from HDL NPs to exosomes. Modified exosomes are stable in serum and can be directly detected using flow cytometry. As proof-of-concept, human serum exosomes were found to express SR-B1 and HDL NPs can be used to label and isolate them. Ultimately, we discovered a natural cellular pathway and nanoparticle-receptor pair that enables exosome modulation, detection and isolation.


  • Synthetic High-Density Lipoprotein-Like Nanoparticles as Cancer Therapy

    by Kaylin M. McMahon, Linda Foit, Nicholas L. Angeloni, Francis J. Giles, Leo I. Gordon, C. Shad Thaxton

    High-density lipoproteins (HDL) are diverse natural nanoparticles that carry cholesterol and are best known for the role that they play in cardiovascular disease. However, due to their unique targeting capabilities, diverse molecular cargo, and natural functions beyond cholesterol transport, it is becoming increasingly appreciated that HDLs are critical to cancer development and progression. Accordingly, this chapter highlights ongoing research focused on the connections between HDL and cancer in order to design new drugs and targeted drug delivery vehicles. Research is focused on synthesizing biomimetic HDL-like nanoparticles (NP) that can be loaded with diverse therapeutic cargo (e.g., chemotherapies, nucleic acids, proteins) and specifically targeted to cancer cells. Beyond drug delivery, new data is emerging that HDL-like NPs may be therapeutically active in certain tumor types, for example, B cell lymphoma. Overall, HDL-like NPs are becoming increasingly appreciated as targeted, biocompatible, and efficient therapies for cancer, and may soon become indispensable agents in the cancer therapeutic armamentarium. Keywords High-density lipoprotein Cholesterol Nanotechnology siRNA Delivery Cancer therapy


  • NanoFlares for the detection, isolation, and culture of live tumor cells from human blood

    by Tiffany L. Halo, Kaylin M. McMahon, Nicholas L. Angeloni, Yilin Xu, Wei Wang, Alyssa B. Chinen, Dmitry Malin, Elena Strekalova, Vincent L. Cryns, Chonghui Cheng, et al.

    Significance: To our knowledge, as the first genetic-based approach for the simultaneous isolation and intracellular genetic analysis of live circulating tumor cells, NanoFlares provide opportunities for invasive cancer study, diagnosis, prognosis, and personalized therapy.


  • Open Access

    Sonic Hedgehog Protein Is Decreased and Penile Morphology Is Altered in Prostatectomy and Diabetic Patients

    by Nicholas L. Angeloni, Christopher W. Bond, Kevin T. McVary, Carol A. Podlasek

    Erectile dysfunction (ED) is a debilitating medical condition and current treatments are ineffective in patients with cavernous nerve (CN) injury, due to penile remodeling and apoptosis. A critical regulator of penile smooth muscle and apoptosis is the secreted protein sonic hedgehog (SHH). SHH protein is decreased in rat prostatectomy and diabetic ED models, SHH inhibition in the penis induces apoptosis and ED, and SHH treatment at the time of CN injury suppresses smooth muscle apoptosis and promotes regeneration of erectile function. Thus SHH treatment has significant translational potential as an ED therapy if similar mechanisms underlie ED development in patients. In this study we quantify SHH protein and morphological changes in corpora cavernosal tissue of control, prostatectomy and diabetic patients and hypothesize that decreased SHH protein is an underlying cause of ED development in prostatectomy and diabetic patients. Our results show significantly decreased SHH protein in prostatectomy and diabetic penis. Morphological remodelling of the penis, including significantly increased apoptotic index and decreased smooth muscle/collagen ratio, accompanies declining SHH. SHH signaling is active in human penis and is altered in a parallel manner to previous observations in the rat. These results suggest that SHH has significant potential to be developed as an ED therapy in prostatectomy and diabetic patients. The increased apoptotic index long after initial injury is suggestive of ongoing remodeling that may be clinically manipulatable.


  • Sonic Hedgehog Is Neuroprotective in the Cavernous Nerve with Crush Injury

    by Nicholas Angeloni, Christopher W. Bond, Daniel Harrington, Samuel Stupp, Carol A. Podlasek

    Introduction The cavernous nerve (CN) is commonly injured during prostatectomy, resulting in erectile dysfunction (ED). Although peripheral nerves have a limited ability to regenerate, a return of function typically does not occur due to irreversible down stream morphological changes in the penis that result from CN injury. We have shown in previous studies that sonic hedgehog (SHH) is critical for CN regeneration and improves erectile function after crush injury. Aims Examine a new direction, to determine if SHH is neuroprotective to the pelvic ganglia (PG)/CN after crush injury. A secondary focus is to examine if SHH signaling decreases with age in the PG/CN. Methods Sprague–Dawley rats underwent bilateral CN crush and SHH and glial fibrillary acidic protein were quantified by western analysis of the PG/CN (N = 6 rats at each time point) at 1, 2, 4, 7, and 14 days, and the apoptotic index was measured in the penis. SHH was quantified by western in the PG/CN with blockade of anterograde transport (N = 4 rats) in comparison to mouse IgG (N = 4 rats). If SHH is neuroprotective was examined at 4 (N = 14 rats) and 7 days (N = 16 rats) of treatment after CN crush. SHH protein was quantified in aging (P200‐300, N = 5 rats) PG/CN in comparison to normal adult (P115‐120, N = 3 rats) PG/CN. Main Outcome Measures SHH pathway was examined in PG via immunohistochemistry, in situ, western, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). Results SHH is neuroprotective in the PG/CN with injury. SHH localization in the PG/CN suggests SHH interaction in neuronal/glial signaling. SHH protein is significantly decreased in the PG/CN after crush injury and in the aged PG/CN. Signals from the PG are required to maintain SHH in the CN. Conclusions There is a window of opportunity immediately after nerve insult in which manipulation of SHH signaling in the nerve microenvironment can affect long‐term regeneration outcome.


  • Sonic Hedgehog Regulates Brain-Derived Neurotrophic Factor in Normal and Regenerating Cavernous Nerves

    by Christopher W. Bond, Nicholas Angeloni, Daniel Harrington, Samuel Stupp, Carol A. Podlasek

    Introduction The cavernous nerve (CN) is commonly injured during prostatectomy. Manipulation of the nerve microenvironment is critical to improve regeneration and develop novel erectile dysfunction therapies. Sonic hedgehog (SHH) treatment promotes CN regeneration. The mechanism of how this occurs is unknown. Brain‐derived neurotrophic factor (BDNF) facilitates return of erectile function after CN injury and it has been suggested in cortical neurons and the sciatic nerve that BDNF may be a target of SHH. Aim To determine if SHH promotes CN regeneration through a BDNF‐dependent mechanism. Methods Sprague Dawley rats underwent (i) bilateral CN crush (N = 15); (ii) SHH treatment of pelvic ganglia (PG)/CN (N = 10); (iii) SHH inhibition in PG/CN (N = 14 rats); (iv) CN crush with SHH treatment of PG/CN (N = 10 rats); (v) CN crush with SHH treatment and BDNF inhibition (N = 14 rats); and (vi) CN injury and SHH treatment of the penis (N = 23). Main Outcome Measures BDNF and glial fibrillary acidic protein were quantified in PG/CN by Western, and a t‐test was used to determine differences. Results In normal rats SHH inhibition in the PG/CN decreased BDNF 34% and SHH treatment increased BDNF 36%. BDNF was increased 44% in response to SHH treatment of crushed CNs, and inhibition of BDNF in crushed CNs treated with SHH protein hampers regeneration. Conclusions SHH regulates BDNF in the normal and regenerating PG/CN. BDNF is part of the mechanism of how SHH promotes regeneration, thus providing an opportunity to further manipulate the nerve microenvironment with combination therapy to enhance regeneration. Bond CW, Angeloni N, Harrington D, Stupp S, and Podlasek CA. Sonic hedgehog regulates brain‐derived neurotrophic factor in normal and regenerating cavernous nerves. J Sex Med 2013;10:730–737.


  • Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers

    by Nicholas L. Angeloni, Christopher W. Bond, Yi Tang, Daniel A. Harrington, Shuming Zhang, Samuel I. Stupp, Kevin E. McKenna, Carol A. Podlasek


  • Peptide Amphiphile Nanofiber Delivery of Sonic Hedgehog Protein to Reduce Smooth Muscle Apoptosis in the Penis After Cavernous Nerve Resection

    by Christopher W. Bond, Nicholas L. Angeloni, Daniel A. Harrington, Samuel I. Stupp, Kevin E. McKenna, Carol A. Podlasek

    Erectile dysfunction (ED) is a serious medical condition that affects 16–82% of prostate cancer patients treated by radical prostatectomy and current treatments are ineffective in 50–60% of prostatectomy patients. The reduced efficacy of treatments makes novel therapeutic approaches to treat ED essential. The secreted protein Sonic hedgehog (SHH) is a critical regulator of penile smooth muscle and apoptosis that is decreased in cavernous nerve (CN) injury and diabetic ED models. Past studies using Affi‐Gel beads have shown SHH protein to be effective in suppressing apoptosis caused by CN injury. We hypothesize that SHH protein delivered via novel peptide amphiphile (PA) nanofibers will be effective in suppressing CN injury‐induced apoptosis. Adult Sprague Dawley rats (n = 50) were used to optimize PA injection in vivo. PA with SHH protein (n = 16) or bovine serum albumin (BSA) (control, n = 14) was injected into adult rats that underwent bilateral CN cut. Rats were sacrificed at 2, 4, and 7 days. Alexa Fluor‐labeled SHH protein was used to determine the target of SHH signaling (n = 3). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and semiquantitative immunohistochemical analysis for SHH protein and cluster differentiation protein three (CD3) were performed. SHH‐PA caused a 25% and 16% reduction in apoptosis at 4 and 7 days after CN injury and a 9.3% and 19% increase in SHH protein at 4 and 7 days after CN injury. CD3 protein was not observed in SHH‐PA‐treated penis. In vitro, 73% of SHH protein diffused from PA within 6 days. Labeled SHH was observed in smooth muscle. PA technology is effective in delivering SHH protein to the penis and SHH is effective in suppressing CN injury‐induced apoptosis. These results suggest substantial translational potential of this methodology and show that only a short duration of SHH treatment is required to impact the apoptotic index. Bond CW, Angeloni NL, Harrington DA, Stupp SI, McKenna KE, and Podlasek CA. Peptide amphiphile nanofiber delivery of Sonic hedgehog protein to reduce smooth muscle apoptosis in the penis after cavernous nerve resection. J Sex Med 2011;8:78–89.